Sotatercept Reduces Risk for Clinical Worsening in Adults With Recently Diagnosed PAH

THURSDAY, Oct. 9, 2025 (HealthDay News) -- The addition of sotatercept, an activin-signaling inhibitor, to background therapy results in a lower risk for clinic